AI in Drug Discovery Market by Process (Target, Lead), Use Case (Repurposing, DE Novo Drug Design [Vaccine] Optimization, Disease Understanding, PK/PD), Therapy (Cancer, CNS), Tool (DL [CNN, GAN]), End User - Global Forecast to 2031
The AI in drug discovery market is anticipated to grow from USD 5.09 billion in 2026 to USD 17.56 billion by 2031, at a CAGR of 28.1% during the forecast period. The market is driven by the increasing adoption of AI to improve R&D productivity, expanding use of multimodal biological datasets, and growing investments in precision medicine and computational drug discovery. According to a 2025 review published in Drug Discovery Today, declining pharmaceutical R&D productivity continues to reshape innovation strategies across the biopharmaceutical industry, prompting companies to increasingly adopt AI-driven platforms to improve research efficiency and accelerate drug discovery. However, challenges related to data quality, model validation, regulatory uncertainty, and integration with existing pharmaceutical R&D workflows continue to influence the pace of market adoption.
Machine learning to be the fastest-growing AI tool segment between 2026 and 2031
By AI tool, the machine learning segment is expected to register the fastest growth during the forecast period as pharmaceutical companies increasingly leverage predictive algorithms to improve decision-making across the drug discovery workflow. Machine learning enables rapid analysis of complex biological, chemical, and clinical datasets, significantly enhancing target identification, hit prioritization, molecular property prediction, and lead optimization. Continuous advancements in deep learning, graph neural networks, and generative AI have further expanded the application of machine learning across small molecule discovery, biologics development, and precision medicine research. Reflecting this trend, in March 2026, NVIDIA expanded its BioNeMo platform with next-generation foundation models and agentic AI capabilities to accelerate biomolecular research and molecular design. As pharmaceutical companies continue to prioritize faster drug development and improved R&D efficiency, machine learning is expected to remain the fastest-growing technology segment in the AI in drug discovery market.
Oncology segment accounted for the largest share of the AI in drug discovery market in 2025
By therapeutic area, the oncology segment accounted for the largest share of the AI in drug discovery market in 2025 due to the high global cancer burden, extensive oncology research pipelines, and increasing demand for precision therapeutics. According to the International Agency for Research on Cancer (IARC), global cancer incidence is projected to increase from 20.6 million new cases in 2024 to 34.4 million by 2050, highlighting the growing need for innovative technologies that can accelerate oncology drug discovery. AI is widely adopted to identify novel therapeutic targets, predict biomarkers, optimize patient stratification, and accelerate the discovery of targeted therapies and immuno-oncology drugs. The availability of large genomic, transcriptomic, proteomic, and clinical datasets has made oncology one of the most data-rich therapeutic areas, enabling AI models to generate more accurate and clinically relevant insights. Pharmaceutical companies continue to prioritize oncology within their R&D portfolios due to its significant commercial potential and the growing demand for personalized cancer therapies. Increasing collaborations between AI companies and oncology-focused biopharmaceutical organizations are further accelerating innovation and reinforcing oncology’s leading position in the AI in drug discovery market.
Europe to exhibit the second-highest CAGR during the forecast period
Europe is expected to register the second-highest growth rate during the forecast period, driven by increasing investments in pharmaceutical innovation, expanding adoption of AI across biomedical research, and a strong regulatory framework supporting trustworthy AI. The region is home to leading pharmaceutical companies, research institutions, and AI-native biotechnology firms that are accelerating the integration of AI into target discovery, molecular design, and precision medicine. The implementation of the European Health Data Space (EHDS) and the EU AI Act is expected to facilitate secure cross-border access to health data while establishing harmonized governance for AI applications in life sciences. In parallel, the proposed Cloud and AI Development Act (CADA) aims to strengthen Europe’s cloud and AI infrastructure by expanding sovereign computing capacity, improving access to high-performance computing resources, and supporting the development of AI innovation across strategic sectors, including healthcare and life sciences. In addition, collaborative programs such as the Innovative Health Initiative (IHI) continue to fund AI-enabled drug discovery projects, including LIGAND-AI, to accelerate therapeutic research through high-quality biological datasets and advanced AI models. Collectively, these initiatives are expected to reinforce its position as the second-fastest-growing regional market for AI in drug discovery.
The breakdown of primary participants is as mentioned below:
Key Players
The key players operating in the AI in drug discovery market include NVIDIA Corporation (US), Schr?dinger, Inc. (US), Recursion (US), Insilico Medicine (US), Google (US), Microsoft Corporation (US), Tempus AI, Inc. (US), Illumina, Inc. (US), XtalPi Inc. (China), and Iktos (France). These companies have adopted strategies such as strategic partnerships, collaborations, product launches, platform enhancements, investments in foundation models and generative AI, mergers and acquisitions, and geographic expansion to strengthen their market presence in the market.
Research Coverage
The report analyzes the AI in drug discovery market. It aims to estimate the market size and future growth potential of various market segments based on process, use case, therapeutic area, player type, AI tool, deployment model, end user, and region. The report also analyzes factors such as drivers, restraints, opportunities, and challenges influencing market growth. It evaluates opportunities across the AI-driven drug discovery ecosystem and assesses the competitive landscape for key stakeholders. The report further analyzes micro markets with respect to their growth trends, prospects, and contributions to the overall AI in drug discovery market. It forecasts market revenue across major regions and provides a comprehensive competitive analysis of leading market participants, including their company profiles, product portfolios, recent developments, and key growth strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their positions in the market.
This report provides insights on:
Machine learning to be the fastest-growing AI tool segment between 2026 and 2031
By AI tool, the machine learning segment is expected to register the fastest growth during the forecast period as pharmaceutical companies increasingly leverage predictive algorithms to improve decision-making across the drug discovery workflow. Machine learning enables rapid analysis of complex biological, chemical, and clinical datasets, significantly enhancing target identification, hit prioritization, molecular property prediction, and lead optimization. Continuous advancements in deep learning, graph neural networks, and generative AI have further expanded the application of machine learning across small molecule discovery, biologics development, and precision medicine research. Reflecting this trend, in March 2026, NVIDIA expanded its BioNeMo platform with next-generation foundation models and agentic AI capabilities to accelerate biomolecular research and molecular design. As pharmaceutical companies continue to prioritize faster drug development and improved R&D efficiency, machine learning is expected to remain the fastest-growing technology segment in the AI in drug discovery market.
Oncology segment accounted for the largest share of the AI in drug discovery market in 2025
By therapeutic area, the oncology segment accounted for the largest share of the AI in drug discovery market in 2025 due to the high global cancer burden, extensive oncology research pipelines, and increasing demand for precision therapeutics. According to the International Agency for Research on Cancer (IARC), global cancer incidence is projected to increase from 20.6 million new cases in 2024 to 34.4 million by 2050, highlighting the growing need for innovative technologies that can accelerate oncology drug discovery. AI is widely adopted to identify novel therapeutic targets, predict biomarkers, optimize patient stratification, and accelerate the discovery of targeted therapies and immuno-oncology drugs. The availability of large genomic, transcriptomic, proteomic, and clinical datasets has made oncology one of the most data-rich therapeutic areas, enabling AI models to generate more accurate and clinically relevant insights. Pharmaceutical companies continue to prioritize oncology within their R&D portfolios due to its significant commercial potential and the growing demand for personalized cancer therapies. Increasing collaborations between AI companies and oncology-focused biopharmaceutical organizations are further accelerating innovation and reinforcing oncology’s leading position in the AI in drug discovery market.
Europe to exhibit the second-highest CAGR during the forecast period
Europe is expected to register the second-highest growth rate during the forecast period, driven by increasing investments in pharmaceutical innovation, expanding adoption of AI across biomedical research, and a strong regulatory framework supporting trustworthy AI. The region is home to leading pharmaceutical companies, research institutions, and AI-native biotechnology firms that are accelerating the integration of AI into target discovery, molecular design, and precision medicine. The implementation of the European Health Data Space (EHDS) and the EU AI Act is expected to facilitate secure cross-border access to health data while establishing harmonized governance for AI applications in life sciences. In parallel, the proposed Cloud and AI Development Act (CADA) aims to strengthen Europe’s cloud and AI infrastructure by expanding sovereign computing capacity, improving access to high-performance computing resources, and supporting the development of AI innovation across strategic sectors, including healthcare and life sciences. In addition, collaborative programs such as the Innovative Health Initiative (IHI) continue to fund AI-enabled drug discovery projects, including LIGAND-AI, to accelerate therapeutic research through high-quality biological datasets and advanced AI models. Collectively, these initiatives are expected to reinforce its position as the second-fastest-growing regional market for AI in drug discovery.
The breakdown of primary participants is as mentioned below:
- By Company Type - Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
- By Designation - Directors: 30%, Managers: 34%, and Others: 36%
- By Region - North America: 40%, Europe: 28%, Asia Pacific: 20%, Latin America: 7%, and Middle East & Africa: 5%
Key Players
The key players operating in the AI in drug discovery market include NVIDIA Corporation (US), Schr?dinger, Inc. (US), Recursion (US), Insilico Medicine (US), Google (US), Microsoft Corporation (US), Tempus AI, Inc. (US), Illumina, Inc. (US), XtalPi Inc. (China), and Iktos (France). These companies have adopted strategies such as strategic partnerships, collaborations, product launches, platform enhancements, investments in foundation models and generative AI, mergers and acquisitions, and geographic expansion to strengthen their market presence in the market.
Research Coverage
The report analyzes the AI in drug discovery market. It aims to estimate the market size and future growth potential of various market segments based on process, use case, therapeutic area, player type, AI tool, deployment model, end user, and region. The report also analyzes factors such as drivers, restraints, opportunities, and challenges influencing market growth. It evaluates opportunities across the AI-driven drug discovery ecosystem and assesses the competitive landscape for key stakeholders. The report further analyzes micro markets with respect to their growth trends, prospects, and contributions to the overall AI in drug discovery market. It forecasts market revenue across major regions and provides a comprehensive competitive analysis of leading market participants, including their company profiles, product portfolios, recent developments, and key growth strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their positions in the market.
This report provides insights on:
- Analysis of key drivers (Rising need to reduce time and cost of drug discovery and development, Growing utilization of AI to predict drug-target interactions for cancer therapy), restraints (Shortage of AI workforce and regulatory frameworks for AI-enabled drug discovery, Increasing AI compute infrastructure costs amid global HBM/DRAM/NAND shortage), opportunities (Accelerating biotech drug discovery, AI-driven single-cell analysis for biomarker and disease-subtype identification), and challenges (Limited availability of high-quality training datasets, Limited real-world clinical validation of AI-derived drug candidates) are factors contributing the growth of the AI in drug discovery market
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and software launches in the AI in drug discovery market
- Market Development: Comprehensive information on high-growth market segments across process, use case, therapeutic area, player type, AI tool, deployment model, end user, and region
- Market Diversification: Exhaustive information on product portfolios, technology advancements, expanding geographic presence, strategic collaborations, investments, and recent developments in the AI in drug discovery market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, technology capabilities, and competitive strengths of leading players in the global AI in drug discovery market, including NVIDIA Corporation (US), Schr?dinger, Inc. (US), Recursion (US), Insilico Medicine (US), Google (US), Microsoft Corporation (US), Tempus AI, Inc. (US), Illumina, Inc. (US), XtalPi Inc. (China), and other major market participants
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SCOPE
1.3.3 INCLUSIONS & EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 AI IN DRUG DISCOVERY MARKET OVERVIEW
3.2 AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT & COUNTRY
3.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Increasing number of cross-industry collaborations and partnerships
4.2.1.2 Rising need to reduce time and cost of drug discovery and development
4.2.1.3 Patent expiry of drugs and need for effective new leads
4.2.1.4 Growing utilization of AI to predict drug-target interactions for cancer therapy
4.2.1.5 Integration of AI-assisted multiomics in drug discovery
4.2.1.6 Growing focus on rare disease treatments for orphan drug development
4.2.2 RESTRAINTS
4.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software
4.2.3 OPPORTUNITIES
4.2.3.1 Leveraging AI for accelerated biotech drug discovery
4.2.3.2 Increased focus on drug discovery in emerging economies
4.2.3.3 Focus on developing human-aware AI systems
4.2.3.4 Growing use of AI in single-cell analysis
4.2.3.5 Easy identification of biomarker and disease subtypes from single-cell data
4.2.3.6 High demand for precision and personalized medicines
4.2.4 CHALLENGES
4.2.4.1 Limited availability of quality data sets
4.2.4.2 Lack of advanced AI tools and training data sets
4.2.4.3 Computational constraints of advanced AI models
4.2.4.4 Lack of high-quality data sets for model training
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 THREAT OF NEW ENTRANTS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 GLOBAL PHARMACEUTICAL R&D EXPENDITURE AND PRODUCTIVITY TRENDS
5.3 VALUE CHAIN ANALYSIS
5.3.1 RESEARCH, DATA GENERATION, AND SCIENTIFIC INPUTS
5.3.2 DATA ENGINEERING & AI INFRASTRUCTURE
5.3.3 AI MODEL & PLATFORM DEVELOPMENT
5.3.4 AI WORKFLOW INTEGRATION & DEPLOYMENT
5.3.5 DRUG DISCOVERY SERVICES & EXPERIMENTAL EXECUTION
5.3.6 VALIDATION, LAB-IN-THE-LOOP, AND CONTINUOUS OPTIMIZATION
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY PLATFORMS, BY KEY PLAYERS (2025)
5.5.2 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY SOFTWARE AND SERVICES, BY REGION (2025)
5.6 KEY CONFERENCES AND EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 CASE STUDY ANALYSIS
5.10 IMPACT OF 2025 US TARIFF – AI IN DRUG DISCOVERY MARKET
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRY/REGION
5.10.4.1 US
5.10.4.2 Europe
5.10.4.3 Asia-Pacific
5.10.5 IMPACT ON END-USE INDUSTRIES
5.10.5.1 Pharmaceutical companies
5.10.5.2 Biotechnology companies
5.10.5.3 CROs and CDMOs
5.10.5.4 Academic and research users
5.10.5.5 Other end users
6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 GENERATIVE AND AGENTIC AI FOR DRUG DISCOVERY
6.1.2 MULTIMODAL AI AND FOUNDATION MODELS
6.1.3 AI-ENABLED AUTONOMOUS LABORATORIES
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 CLOUD COMPUTING AND HIGH-PERFORMANCE COMPUTING
6.2.2 HIGH-THROUGHPUT SCREENING AND LABORATORY AUTOMATION
6.3 ADJACENT TECHNOLOGIES
6.3.1 MULTIOMICS AND SINGLE-CELL TECHNOLOGIES
6.3.2 DIGITAL TWINS AND IN-SILICO CLINICAL TECHNOLOGIES
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 PATENT PUBLICATION TRENDS FOR AI IN DRUG DISCOVERY MARKET
6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
6.6 FUTURE APPLICATIONS
6.6.1 AUTONOMOUS END-TO-END DRUG DISCOVERY
6.6.2 AI-DRIVEN PRECISION DRUG DISCOVERY AND PATIENT-SPECIFIC THERAPEUTICS
6.6.3 AI-ENABLED DIGITAL AND VIRTUAL DRUG DEVELOPMENT
7 REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.1.3 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 INTRODUCTION
8.2 DECISION-MAKING PROCESS
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2 BUYING CRITERIA
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5 UNMET NEEDS FROM VARIOUS END USERS
8.5.1 UNMET NEEDS
8.5.2 END USER EXPECTATIONS
8.6 MARKET PROFITABILITY
9 AI IN DRUG DISCOVERY MARKET, BY PROCESS
9.1 INTRODUCTION
9.2 TARGET IDENTIFICATION & SELECTION
9.2.1 INCREASED DEMAND FOR PERSONALIZED MEDICINES AND HIGH INVESTMENT IN PHARMACEUTICAL R&D TO FUEL MARKET GROWTH
9.3 TARGET VALIDATION
9.3.1 RISING EMPHASIS ON AVOIDING LATE-STAGE FAILURE IN DRUG DISCOVERY TO BOOST MARKET GROWTH
9.4 HIT IDENTIFICATION & PRIORITIZATION
9.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION
9.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
9.5.1 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION TO IMPROVE NEW DRUG POTENCY WITHOUT INCREASING LIPOPHILICITY
9.6 LEAD OPTIMIZATION
9.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST MARKET GROWTH
9.7 CANDIDATE SELECTION & VALIDATION
9.7.1 HIGH POSSIBILITY OF CLINICAL DRUG FAILURE TO SPUR ADOPTION OF CANDIDATE VALIDATION SERVICES
10 AI IN DRUG DISCOVERY MARKET, BY AI TOOL
10.1 INTRODUCTION
10.2 MACHINE LEARNING
10.2.1 INCREASING AVAILABILITY OF COMPLEX BIOLOGICAL AND CHEMICAL DATASETS DRIVES ADOPTION
10.2.2 DEEP LEARNING
10.2.2.1 Ability to capture complex nonlinear relationships across multimodal biological and molecular data – key driver
10.2.2.2 Transformer-based architectures
10.2.2.2.1 Growing volumes of sequential, multimodal, and unstructured scientific data drives market
10.2.2.3 Graph neural networks (GNN)
10.2.2.3.1 Need to understand molecular structure and complex biological relationships supports GNN adoption
10.2.2.4 Convolutional neural networks (CNN)
10.2.2.4.1 Expansion of image-based and 3D structural analysis boosts adoption
10.2.2.5 Diffusion and flow-based models
10.2.2.5.1 Increasing demand for controlled generation of novel molecules and proteins accelerates segment growth
10.2.2.6 Generative adversarial networks (GAN) & variational autoencoders (VAE)
10.2.2.6.1 Growing demand for computational exploration of chemical space supports growth
10.2.2.7 Recurrent & Sequence Models (RNN, LSTM)
10.2.2.7.1 Continued need to model sequential chemical and biological information sustains demand
10.2.2.8 Other deep learning technologies
10.2.2.8.1 Emergence of specialized neural architectures expands applications across complex discovery workflows
10.2.3 SUPERVISED LEARNING
10.2.3.1 Growing availability of experimentally validated datasets supports segment
10.2.4 SELF-SUPERVISED & REPRESENTATION LEARNING
10.2.4.1 Shortage of labeled biological data and growing availability of unlabeled datasets drive adoption
10.2.5 REINFORCEMENT LEARNING
10.2.5.1 Need to optimize molecules and experimental decisions across multiple objectives drives adoption
10.2.6 UNSUPERVISED LEARNING
10.2.6.1 Increasing complexity of biological datasets to boost segment
10.2.7 OTHER MACHINE LEARNING TECHNOLOGIES
10.2.7.1 Need to extract value from partially labeled and heterogeneous datasets supports segment
10.3 GENERATIVE AI
10.3.1 ABILITY TO DESIGN NOVEL MOLECULES AND BIOLOGICAL STRUCTURES ACCELERATES ADOPTION
10.3.2 MOLECULAR GENERATIVE MODELS
10.3.2.1 Need to explore larger chemical spaces and simultaneously optimize multiple molecular properties – segment driver
10.3.3 PROTEIN & BIOLOGICS GENERATIVE MODELS
10.3.3.1 Growing demand for engineered proteins, antibodies, and other biologics expands applications
10.3.4 LARGE LANGUAGE MODELS (LLMS)
10.3.4.1 Rapid growth of scientific literature and unstructured research data increases demand
10.4 FOUNDATION MODELS
10.4.1 NEED FOR REUSABLE AI MODELS TO LEARN FROM LARGE-SCALE, MULTIMODAL BIOLOGICAL DATASETS DRIVES ADOPTION
10.4.2 CHEMISTRY FOUNDATION MODELS
10.4.2.1 Increasing need for reusable molecular representation and scalable chemical intelligence drives segment
10.4.3 PROTEIN LANGUAGE MODELS
10.4.3.1 Growing demand for protein engineering and functional prediction accelerates adoption
10.4.4 BIOLOGY AND MULTIOMICS FOUNDATION MODELS
10.4.4.1 Increasing integration of genomic, transcriptomic, proteomic, and cellular data – key driver
10.5 AGENTIC AI & AI CO-SCIENTISTS
10.5.1 GROWTH DRIVEN BY DEMAND FOR AUTONOMOUS RESEARCH WORKFLOWS AND IMPROVED SCIENTIST PRODUCTIVITY
10.5.2 AUTONOMOUS RESEARCH AGENTS & WORKFLOW ORCHESTRATION
10.5.2.1 Need to automate complex multi-step research processes drives adoption
10.5.3 MULTI-AGENT REASONING SYSTEMS
10.5.3.1 Increasing complexity of scientific problems creates demand
10.5.4 LAB-IN-THE-LOOP & CLOSED-LOOP EXPERIMENTATION
10.5.4.1 Integration of AI with automated laboratories enables continuous design–build–test–learn workflows
10.6 KNOWLEDGE GRAPHS AND SEMANTIC REASONING
10.6.1 NEED TO CONNECT FRAGMENTED SCIENTIFIC INFORMATION AND IDENTIFY HIDDEN RELATIONSHIPS DRIVES SEGMENT
10.7 NATURAL LANGUAGE PROCESSING (NLP)
10.7.1 EXPLOSION OF SCIENTIFIC LITERATURE, PATENTS, AND UNSTRUCTURED R&D INFORMATION DRIVES NLP ADOPTION
10.8 COMPUTER VISION & IMAGE ANALYSIS
10.8.1 INCREASING USE OF HIGH-CONTENT SCREENING, MICROSCOPY, AND PHENOTYPIC ASSAYS EXPANDS APPLICATIONS
10.9 PHYSICS-BASED & HYBRID AI METHODS
10.9.1 NEED FOR MECHANISTIC UNDERSTANDING AND IMPROVED ACCURACY IN MOLECULAR MODELING DRIVES SEGMENT
11 AI IN DRUG DISCOVERY MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 GROWING PRESSURE TO ACCELERATE R&D PRODUCTIVITY AND REDUCE DRUG DISCOVERY COSTS DRIVES SEGMENT
11.2.2 LARGE PHARMACEUTICAL COMPANIES
11.2.2.1 High R&D expenditure and increasing need to improve pipeline productivity accelerate AI adoption
11.2.3 SMALL & MID-SIZED BIOTECHNOLOGY COMPANIES
11.2.3.1 Limited internal resources and need for differentiated pipelines increase reliance on AI-enabled discovery
11.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CDMOS
11.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY ACTIVITIES DRIVES GROWTH
11.4 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS
11.4.1 GROWING AVAILABILITY OF RESEARCH FUNDING AND ADVANCED AI CAPABILITIES EXPANDS GROWTH
12 AI IN DRUG DISCOVERY MARKET, BY USE CASE
12.1 INTRODUCTION
12.2 UNDERSTANDING DISEASE BIOLOGY
12.2.1 INCREASED FOCUS ON UNDERSTANDING DISEASES TO IMPROVE RESEARCH DATA QUALITY AND QUANTITY
12.2.2 EVIDENCE SYNTHESIS AND SCIENTIFIC LITERATURE INTELLIGENCE
12.2.2.1 Rapid data analysis – key demand driver
12.2.3 MULTIOMICS INTEGRATION & TARGET-DISEASE ASSOCIATION
12.2.3.1 Growing integration of genomic, transcriptomic, proteomic, metabolomic, and other biological datasets to drive market
12.2.4 EXPERIMENT DESIGN & REAGENT/MODEL SELECTION
12.2.4.1 Growing complexity of disease biology and experiment design boosts demand
12.3 PROTEIN STRUCTURE & INTERACTION PREDICTION
12.3.1 ADVANCES IN AI-POWERED PROTEIN INTERACTION PREDICTION ACCELERATE STRUCTURE-BASED DRUG DISCOVERY
12.4 DRUG REPURPOSING
12.4.1 INCREASING ADOPTION OF AI PLATFORMS FOR SYSTEMATIC DRUG REPURPOSING
12.5 DE NOVO DRUG DESIGN
12.5.1 SMALL MOLECULE DESIGN
12.5.1.1 Increasing use of virtual screening and simulation techniques to drive growth
12.5.2 VACCINE DESIGN
12.5.2.1 Availability of well-validated AI tools to boost market growth
12.5.3 ANTIBODY & OTHER BIOLOGICS DESIGN
12.5.3.1 Advancements in protein modeling to propel segment growth
12.5.4 PROTEIN & ENZYME DESIGN
12.5.4.1 Protein designing to propel segment growth
12.6 DRUG OPTIMIZATION
12.6.1 SMALL MOLECULE OPTIMIZATION
12.6.1.1 Generative models for potential modifications in molecular structures to aid market growth
12.6.2 VACCINE OPTIMIZATION
12.6.2.1 Effective prediction of vaccine formulations and adjustment of delivery vectors to drive growth
12.6.3 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION
12.6.3.1 Increasing adoption of machine learning to predict protein structures to augment segment growth
12.7 SAFETY & TOXICITY
12.7.1 FOCUS ON ADVANCED OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO DRIVE MARKET
13 AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT
13.1 INTRODUCTION
13.2 ON-PREMISE SOLUTIONS
13.2.1 GROWING DEMAND FOR DATA SOVEREIGNTY, IP PROTECTION, AND CONTROL OVER PROPRIETARY R&D DATA SUPPORTS GROWTH DEPLOYMENT
13.3 CLOUD-BASED SOLUTIONS
13.3.1 NEED FOR SCALABLE COMPUTING, RAPID AI DEPLOYMENT, AND COST-EFFICIENT ACCESS TO ADVANCED INFRASTRUCTURE - KEY DRIVERS
13.3.2 PUBLIC CLOUD
13.3.2.1 Elastic computing capacity and access to advanced AI infrastructure drive adoption
13.3.3 PRIVATE CLOUD/VPC/SOVEREIGN DEPLOYMENT
13.3.3.1 Increasing data-security, IP-protection, and data-residency requirements strengthen demand
13.4 HYBRID SOLUTIONS
13.4.1 NEED TO BALANCE COMPUTATIONAL SCALABILITY WITH CONTROL OVER SENSITIVE R&D DATA ACCELERATES ADOPTION
14 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
14.1 INTRODUCTION
14.2 ONCOLOGY
14.2.1 HIGH PREVALENCE OF ONCOLOGY AND SHORTAGE OF EFFECTIVE ONCOLOGY DRUGS TO DRIVE MARKET GROWTH
14.3 INFECTIOUS DISEASES
14.3.1 RISING ANTIMICROBIAL RESISTANCE AND NEED FOR NOVEL ANTI-INFECTIVE THERAPIES TO DRIVE GROWTH
14.4 NEUROLOGY
14.4.1 HIGH DISEASE COMPLEXITY AND LIMITED TREATMENT OPTIONS DRIVE DEMAND FOR AI-ENABLED DISCOVERY
14.5 CARDIOVASCULAR DISEASES
14.5.1 GROWING CARDIOVASCULAR DISEASE BURDEN AND NEED FOR NOVEL THERAPEUTIC TARGETS BOOST GROWTH
14.6 METABOLIC DISEASES
14.6.1 RISING PREVALENCE OF OBESITY AND METABOLIC DISORDERS ACCELERATES DEMAND FOR INNOVATIVE THERAPIES
14.7 IMMUNOLOGY
14.7.1 COMPLEX IMMUNE MECHANISMS AND GROWING DEMAND FOR TARGETED THERAPIES DRIVE AI ADOPTION
14.8 RARE & GENETIC DISORDERS
14.8.1 LIMITED TREATMENT OPTIONS AND FRAGMENTED DISEASE DATA DRIVE AI-ENABLED DRUG DISCOVERY
14.9 MENTAL HEALTH DISORDERS
14.9.1 HIGH UNMET NEED AND LIMITED UNDERSTANDING OF DISEASE MECHANISMS DRIVE SEGMENT GROWTH
14.10 OTHER THERAPEUTIC AREAS
14.10.1 EXPANDING APPLICATION OF AI ACROSS UNDEREXPLORED DISEASE AREAS DRIVES MARKET GROWTH
15 AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE
15.1 INTRODUCTION
15.2 END-TO-END SOLUTION PROVIDERS
15.2.1 INCREASING ADOPTION OF INTEGRATED AI PLATFORMS ACROSS DRUG DISCOVERY WORKFLOW DRIVES GROWTH
15.3 NICHE/POINT SOLUTION PROVIDERS
15.3.1 GROWING DEMAND FOR SPECIALIZED AI CAPABILITIES TARGETING COMPLEX DISCOVERY CHALLENGES TO DRIVE GROWTH
15.4 AI TECHNOLOGY PROVIDERS
15.4.1 RAPID ADVANCES IN GENERATIVE AI, FOUNDATION MODELS, AND AGENTIC AI ACCELERATE DEMAND
15.5 COMPUTE & INFRASTRUCTURE PROVIDERS
15.5.1 GROWING COMPUTATIONAL REQUIREMENTS OF ADVANCED AI MODELS DRIVE DEMAND
15.6 BUSINESS PROCESS SERVICE PROVIDERS
15.6.1 INCREASING OUTSOURCING OF SPECIALIZED AI-ENABLED DISCOVERY ACTIVITIES DRIVES GROWTH
16 AI IN DRUG DISCOVERY MARKET, BY REGION
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
16.2.2 US
16.2.2.1 Strong pharma–AI ecosystem and high R&D investment drives demand
16.2.3 CANADA
16.2.3.1 Strong AI research base and growing biopharma innovation – key drivers
16.3 EUROPE
16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
16.3.2 GERMANY
16.3.2.1 Availability of advanced computing and research infrastructure – key market driver
16.3.3 UK
16.3.3.1 Increasing investment in AI-based molecular design drives demand
16.3.4 SWITZERLAND
16.3.4.1 Strong pharmaceutical and biotechnology ecosystem to boost market
16.3.5 FRANCE
16.3.5.1 Large-scale AI investment by pharmaceutical companies – key driver
16.3.6 ITALY
16.3.6.1 Market driven by country’s strong pharmaceutical and life sciences ecosystem
16.3.7 SPAIN
16.3.7.1 Expansion of AI-enabled biotechnology research drives demand
16.3.8 REST OF EUROPE
16.3.8.1 Growing pharmaceutical R&D and public-sector AI adoption to drive market
16.4 ASIA PACIFIC
16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
16.4.2 JAPAN
16.4.2.1 Increasing pharmaceutical investment in AI and robotics drives demand
16.4.3 CHINA
16.4.3.1 Growth of AI-native biotech companies boosts demand
16.4.4 INDIA
16.4.4.1 Large pharmaceutical and biotechnology ecosystem to propel market
16.4.5 SOUTH KOREA
16.4.5.1 Government support for AI-based drug discovery to boost market
16.4.6 AUSTRALIA
16.4.6.1 Market driven by strong government support for AI and medical research
16.4.7 REST OF ASIA PACIFIC
16.4.7.1 Growth of regional pharmaceutical and biotechnology capabilities to boost market
16.5 LATIN AMERICA
16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
16.5.2 BRAZIL
16.5.2.1 Expanding pharmaceutical R&D and emerging AI-biotech ecosystem act as major drivers
16.5.3 MEXICO
16.5.3.1 Multinational pharmaceutical activity and government-backed research to drive market
16.5.4 REST OF LATIN AMERICA
16.5.4.1 Growing research base for AI to drive market
16.6 MIDDLE EAST & AFRICA
16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
16.6.2 GCC COUNTRIES
16.6.2.1 National AI strategies and growing technology partnerships act as major drivers
16.6.3 SAUDI ARABIA
16.6.3.1 Government investment in biotechnology and life sciences propels market
16.6.4 UAE
16.6.4.1 Government-led AI and biotechnology investment boosts market
16.6.5 REST OF GCC
16.6.5.1 International AI-drug discovery partnerships drive demand
16.6.6 SOUTH AFRICA
16.6.6.1 Strong domestic drug-discovery research base drives market
16.6.7 REST OF MIDDLE EAST & AFRICA
16.6.7.1 Expansion of local pharmaceutical and biomanufacturing capabilities drives demand
17 COMPETITIVE LANDSCAPE
17.1 OVERVIEW
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET
17.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
17.4 MARKET SHARE ANALYSIS, 2025
17.5 BRAND COMPARISON
17.6 VALUATION & FINANCIAL METRICS
17.6.1 FINANCIAL METRICS
17.6.2 COMPANY VALUATION
17.7 COMPANY EVALUATION MATRIX
17.7.1 STARS
17.7.2 EMERGING LEADERS
17.7.3 PERVASIVE PLAYERS
17.7.4 PARTICIPANTS
17.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
17.7.5.1 Company footprint
17.7.5.2 Region footprint
17.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.8.1 PROGRESSIVE COMPANIES
17.8.2 RESPONSIVE COMPANIES
17.8.3 DYNAMIC COMPANIES
17.8.4 STARTING BLOCKS
17.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
17.8.5.1 Detailed list of key startups/SMEs
17.8.5.2 Competitive benchmarking of startups/SMEs
17.9 COMPETITIVE SCENARIO
17.9.1 PRODUCT/SERVICE LAUNCHES
17.9.2 DEALS
17.9.3 EXPANSIONS
17.9.4 OTHER DEVELOPMENTS
18 COMPANY PROFILES
18.1 KEY PLAYERS
18.1.1 NVIDIA CORPORATION
18.1.1.1 Business overview
18.1.1.2 Products/Services offered
18.1.1.3 Recent developments
18.1.1.3.1 Product/Service launches & approvals
18.1.1.3.2 Deals
18.1.1.3.3 Other developments
18.1.1.4 MnM view
18.1.1.4.1 Right to win
18.1.1.4.2 Strategic choices
18.1.1.4.3 Weaknesses & competitive threats
18.1.2 ALPHABET INC.
18.1.2.1 Business overview
18.1.2.2 Products/Services offered
18.1.2.3 Recent developments
18.1.2.3.1 Product launches & approvals
18.1.2.3.2 Deals
18.1.2.3.3 Other developments
18.1.2.4 MnM view
18.1.2.4.1 Right to win
18.1.2.4.2 Strategic choices
18.1.2.4.3 Weaknesses & competitive threats
18.1.3 RECURSION
18.1.3.1 Business overview
18.1.3.2 Products/Services offered
18.1.3.3 Recent developments
18.1.3.3.1 Product/Service launches
18.1.3.3.2 Deals
18.1.3.3.3 Expansions
18.1.3.4 MnM view
18.1.3.4.1 Right to win
18.1.3.4.2 Strategic choices
18.1.3.4.3 Weaknesses & competitive threats
18.1.4 INSILICO MEDICINE
18.1.4.1 Business overview
18.1.4.2 Products/Services offered
18.1.4.3 Recent developments
18.1.4.3.1 Product/Service launches
18.1.4.3.2 Deals
18.1.4.3.3 Other developments
18.1.4.3.4 expansions
18.1.4.4 MnM view
18.1.4.4.1 Right to win
18.1.4.4.2 Strategic choices
18.1.4.4.3 Weaknesses & competitive threats
18.1.5 SCHR?DINGER, INC.
18.1.5.1 Business overview
18.1.5.2 Products/Services offered
18.1.5.3 Recent developments
18.1.5.3.1 Deals
18.1.5.3.2 Other developments
18.1.5.4 MnM view
18.1.5.4.1 Right to win
18.1.5.4.2 Strategic choices
18.1.5.4.3 Weaknesses & competitive threats
18.1.6 BENEVOLENTAI
18.1.6.1 Business overview
18.1.6.2 Products/Services offered
18.1.6.3 Recent developments
18.1.6.3.1 Deals
18.1.7 MICROSOFT CORPORATION
18.1.7.1 Business overview
18.1.7.2 Products /Services offered
18.1.7.3 Recent developments
18.1.7.3.1 Product/Service launches & approvals
18.1.7.3.2 Deals
18.1.8 NUMERION LABS
18.1.8.1 Business overview
18.1.8.2 Products/Services offered
18.1.9 ILLUMINA, INC.
18.1.9.1 Business overview
18.1.9.2 Products/Services offered
18.1.9.3 Recent developments
18.1.9.3.1 Product/Service launches
18.1.9.3.2 Deals
18.1.10 XTALPI INC.
18.1.10.1 Business overview
18.1.10.2 Products/Services offered
18.1.10.3 Recent developments
18.1.10.3.1 Deals
18.1.11 IKTOS
18.1.11.1 Business overview
18.1.11.2 Products/Services offered
18.1.11.3 Recent developments
18.1.11.3.1 Deals
18.1.11.3.2 Other developments
18.1.12 TEMPUS AI, INC.
18.1.12.1 Business overview
18.1.12.2 Products/Services offered
18.1.12.3 Recent developments
18.1.12.3.1 Product/Service launches
18.1.12.3.2 Deals
18.1.13 DEEP GENOMICS, INC.
18.1.13.1 Business overview
18.1.13.2 Products/Services offered
18.1.13.3 Recent developments
18.1.13.3.1 Product/Service launches & approvals
18.1.14 VERGE LABS
18.1.14.1 Business overview
18.1.14.2 Products /Services offered
18.1.14.3 Recent developments
18.1.14.3.1 Deals
18.1.15 BENCHSCI
18.1.15.1 Business overview
18.1.15.2 Products/Services offered
18.1.15.3 Recent developments
18.1.15.3.1 Product/Service launches & approvals
18.1.15.3.2 Deals
18.1.15.3.3 Other developments
18.1.16 INSITRO
18.1.16.1 Business overview
18.1.16.2 Products/Services offered
18.1.16.3 Recent developments
18.1.16.3.1 Deals
18.1.16.3.2 Other developments
18.1.17 VALO HEALTH
18.1.17.1 Business overview
18.1.17.2 Products/Services offered
18.1.17.3 Recent developments
18.1.17.3.1 Deals
18.1.17.3.2 Other developments
18.1.18 BPGBIO, INC.
18.1.18.1 Business overview
18.1.18.2 Products/Services offered
18.1.18.3 Recent developments
18.1.18.3.1 Deals
18.1.19 GENERATE:BIOMEDICINES
18.1.19.1 Business overview
18.1.19.2 Products/Services offered
18.1.19.3 Recent developments
18.1.19.3.1 Product/Service launches
18.1.19.3.2 Deals
18.1.19.3.3 Expansions
18.1.20 CERTARA, INC.
18.1.20.1 Business overview
18.1.20.2 Products/Services offered
18.1.20.3 Recent developments
18.1.20.3.1 Product/Service launches & approvals
18.1.20.3.2 Deals
18.2 OTHER EMERGING PLAYERS
18.2.1 XAIRA THERAPEUTICS
18.2.2 IAMBIC THERAPEUTICS, INC.
18.2.3 GENESIS MOLECULAR AI
18.2.4 CRADLE BIO
18.2.5 ISOMORPHIC LABS
19 RESEARCH METHODOLOGY
19.1 RESEARCH APPROACH
19.1.1 SECONDARY RESEARCH
19.1.1.1 Key data from secondary sources
19.1.2 PRIMARY RESEARCH
19.1.2.1 Primary sources
19.1.2.2 Key data from primary sources
19.1.2.3 Breakdown of primaries
19.1.2.4 Insights from primary experts
19.2 RESEARCH METHODOLOGY DESIGN
19.3 MARKET SIZE ESTIMATION
19.4 MARKET BREAKDOWN DATA TRIANGULATION
19.5 MARKET SHARE ESTIMATION
19.6 STUDY ASSUMPTIONS
19.7 RESEARCH LIMITATIONS
19.7.1 METHODOLOGY-RELATED LIMITATIONS
19.8 RISK ASSESSMENT
20 APPENDIX
20.1 DISCUSSION GUIDE
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3 CUSTOMIZATION OPTIONS
20.4 RELATED REPORTS
20.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SCOPE
1.3.3 INCLUSIONS & EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 AI IN DRUG DISCOVERY MARKET OVERVIEW
3.2 AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT & COUNTRY
3.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Increasing number of cross-industry collaborations and partnerships
4.2.1.2 Rising need to reduce time and cost of drug discovery and development
4.2.1.3 Patent expiry of drugs and need for effective new leads
4.2.1.4 Growing utilization of AI to predict drug-target interactions for cancer therapy
4.2.1.5 Integration of AI-assisted multiomics in drug discovery
4.2.1.6 Growing focus on rare disease treatments for orphan drug development
4.2.2 RESTRAINTS
4.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software
4.2.3 OPPORTUNITIES
4.2.3.1 Leveraging AI for accelerated biotech drug discovery
4.2.3.2 Increased focus on drug discovery in emerging economies
4.2.3.3 Focus on developing human-aware AI systems
4.2.3.4 Growing use of AI in single-cell analysis
4.2.3.5 Easy identification of biomarker and disease subtypes from single-cell data
4.2.3.6 High demand for precision and personalized medicines
4.2.4 CHALLENGES
4.2.4.1 Limited availability of quality data sets
4.2.4.2 Lack of advanced AI tools and training data sets
4.2.4.3 Computational constraints of advanced AI models
4.2.4.4 Lack of high-quality data sets for model training
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 THREAT OF NEW ENTRANTS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 GLOBAL PHARMACEUTICAL R&D EXPENDITURE AND PRODUCTIVITY TRENDS
5.3 VALUE CHAIN ANALYSIS
5.3.1 RESEARCH, DATA GENERATION, AND SCIENTIFIC INPUTS
5.3.2 DATA ENGINEERING & AI INFRASTRUCTURE
5.3.3 AI MODEL & PLATFORM DEVELOPMENT
5.3.4 AI WORKFLOW INTEGRATION & DEPLOYMENT
5.3.5 DRUG DISCOVERY SERVICES & EXPERIMENTAL EXECUTION
5.3.6 VALIDATION, LAB-IN-THE-LOOP, AND CONTINUOUS OPTIMIZATION
5.4 ECOSYSTEM ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY PLATFORMS, BY KEY PLAYERS (2025)
5.5.2 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY SOFTWARE AND SERVICES, BY REGION (2025)
5.6 KEY CONFERENCES AND EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 CASE STUDY ANALYSIS
5.10 IMPACT OF 2025 US TARIFF – AI IN DRUG DISCOVERY MARKET
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.10.4 IMPACT ON COUNTRY/REGION
5.10.4.1 US
5.10.4.2 Europe
5.10.4.3 Asia-Pacific
5.10.5 IMPACT ON END-USE INDUSTRIES
5.10.5.1 Pharmaceutical companies
5.10.5.2 Biotechnology companies
5.10.5.3 CROs and CDMOs
5.10.5.4 Academic and research users
5.10.5.5 Other end users
6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 GENERATIVE AND AGENTIC AI FOR DRUG DISCOVERY
6.1.2 MULTIMODAL AI AND FOUNDATION MODELS
6.1.3 AI-ENABLED AUTONOMOUS LABORATORIES
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 CLOUD COMPUTING AND HIGH-PERFORMANCE COMPUTING
6.2.2 HIGH-THROUGHPUT SCREENING AND LABORATORY AUTOMATION
6.3 ADJACENT TECHNOLOGIES
6.3.1 MULTIOMICS AND SINGLE-CELL TECHNOLOGIES
6.3.2 DIGITAL TWINS AND IN-SILICO CLINICAL TECHNOLOGIES
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 PATENT PUBLICATION TRENDS FOR AI IN DRUG DISCOVERY MARKET
6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
6.6 FUTURE APPLICATIONS
6.6.1 AUTONOMOUS END-TO-END DRUG DISCOVERY
6.6.2 AI-DRIVEN PRECISION DRUG DISCOVERY AND PATIENT-SPECIFIC THERAPEUTICS
6.6.3 AI-ENABLED DIGITAL AND VIRTUAL DRUG DEVELOPMENT
7 REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS
7.1.2 REGULATORY FRAMEWORK
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.1.3 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 INTRODUCTION
8.2 DECISION-MAKING PROCESS
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2 BUYING CRITERIA
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5 UNMET NEEDS FROM VARIOUS END USERS
8.5.1 UNMET NEEDS
8.5.2 END USER EXPECTATIONS
8.6 MARKET PROFITABILITY
9 AI IN DRUG DISCOVERY MARKET, BY PROCESS
9.1 INTRODUCTION
9.2 TARGET IDENTIFICATION & SELECTION
9.2.1 INCREASED DEMAND FOR PERSONALIZED MEDICINES AND HIGH INVESTMENT IN PHARMACEUTICAL R&D TO FUEL MARKET GROWTH
9.3 TARGET VALIDATION
9.3.1 RISING EMPHASIS ON AVOIDING LATE-STAGE FAILURE IN DRUG DISCOVERY TO BOOST MARKET GROWTH
9.4 HIT IDENTIFICATION & PRIORITIZATION
9.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION
9.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
9.5.1 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION TO IMPROVE NEW DRUG POTENCY WITHOUT INCREASING LIPOPHILICITY
9.6 LEAD OPTIMIZATION
9.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST MARKET GROWTH
9.7 CANDIDATE SELECTION & VALIDATION
9.7.1 HIGH POSSIBILITY OF CLINICAL DRUG FAILURE TO SPUR ADOPTION OF CANDIDATE VALIDATION SERVICES
10 AI IN DRUG DISCOVERY MARKET, BY AI TOOL
10.1 INTRODUCTION
10.2 MACHINE LEARNING
10.2.1 INCREASING AVAILABILITY OF COMPLEX BIOLOGICAL AND CHEMICAL DATASETS DRIVES ADOPTION
10.2.2 DEEP LEARNING
10.2.2.1 Ability to capture complex nonlinear relationships across multimodal biological and molecular data – key driver
10.2.2.2 Transformer-based architectures
10.2.2.2.1 Growing volumes of sequential, multimodal, and unstructured scientific data drives market
10.2.2.3 Graph neural networks (GNN)
10.2.2.3.1 Need to understand molecular structure and complex biological relationships supports GNN adoption
10.2.2.4 Convolutional neural networks (CNN)
10.2.2.4.1 Expansion of image-based and 3D structural analysis boosts adoption
10.2.2.5 Diffusion and flow-based models
10.2.2.5.1 Increasing demand for controlled generation of novel molecules and proteins accelerates segment growth
10.2.2.6 Generative adversarial networks (GAN) & variational autoencoders (VAE)
10.2.2.6.1 Growing demand for computational exploration of chemical space supports growth
10.2.2.7 Recurrent & Sequence Models (RNN, LSTM)
10.2.2.7.1 Continued need to model sequential chemical and biological information sustains demand
10.2.2.8 Other deep learning technologies
10.2.2.8.1 Emergence of specialized neural architectures expands applications across complex discovery workflows
10.2.3 SUPERVISED LEARNING
10.2.3.1 Growing availability of experimentally validated datasets supports segment
10.2.4 SELF-SUPERVISED & REPRESENTATION LEARNING
10.2.4.1 Shortage of labeled biological data and growing availability of unlabeled datasets drive adoption
10.2.5 REINFORCEMENT LEARNING
10.2.5.1 Need to optimize molecules and experimental decisions across multiple objectives drives adoption
10.2.6 UNSUPERVISED LEARNING
10.2.6.1 Increasing complexity of biological datasets to boost segment
10.2.7 OTHER MACHINE LEARNING TECHNOLOGIES
10.2.7.1 Need to extract value from partially labeled and heterogeneous datasets supports segment
10.3 GENERATIVE AI
10.3.1 ABILITY TO DESIGN NOVEL MOLECULES AND BIOLOGICAL STRUCTURES ACCELERATES ADOPTION
10.3.2 MOLECULAR GENERATIVE MODELS
10.3.2.1 Need to explore larger chemical spaces and simultaneously optimize multiple molecular properties – segment driver
10.3.3 PROTEIN & BIOLOGICS GENERATIVE MODELS
10.3.3.1 Growing demand for engineered proteins, antibodies, and other biologics expands applications
10.3.4 LARGE LANGUAGE MODELS (LLMS)
10.3.4.1 Rapid growth of scientific literature and unstructured research data increases demand
10.4 FOUNDATION MODELS
10.4.1 NEED FOR REUSABLE AI MODELS TO LEARN FROM LARGE-SCALE, MULTIMODAL BIOLOGICAL DATASETS DRIVES ADOPTION
10.4.2 CHEMISTRY FOUNDATION MODELS
10.4.2.1 Increasing need for reusable molecular representation and scalable chemical intelligence drives segment
10.4.3 PROTEIN LANGUAGE MODELS
10.4.3.1 Growing demand for protein engineering and functional prediction accelerates adoption
10.4.4 BIOLOGY AND MULTIOMICS FOUNDATION MODELS
10.4.4.1 Increasing integration of genomic, transcriptomic, proteomic, and cellular data – key driver
10.5 AGENTIC AI & AI CO-SCIENTISTS
10.5.1 GROWTH DRIVEN BY DEMAND FOR AUTONOMOUS RESEARCH WORKFLOWS AND IMPROVED SCIENTIST PRODUCTIVITY
10.5.2 AUTONOMOUS RESEARCH AGENTS & WORKFLOW ORCHESTRATION
10.5.2.1 Need to automate complex multi-step research processes drives adoption
10.5.3 MULTI-AGENT REASONING SYSTEMS
10.5.3.1 Increasing complexity of scientific problems creates demand
10.5.4 LAB-IN-THE-LOOP & CLOSED-LOOP EXPERIMENTATION
10.5.4.1 Integration of AI with automated laboratories enables continuous design–build–test–learn workflows
10.6 KNOWLEDGE GRAPHS AND SEMANTIC REASONING
10.6.1 NEED TO CONNECT FRAGMENTED SCIENTIFIC INFORMATION AND IDENTIFY HIDDEN RELATIONSHIPS DRIVES SEGMENT
10.7 NATURAL LANGUAGE PROCESSING (NLP)
10.7.1 EXPLOSION OF SCIENTIFIC LITERATURE, PATENTS, AND UNSTRUCTURED R&D INFORMATION DRIVES NLP ADOPTION
10.8 COMPUTER VISION & IMAGE ANALYSIS
10.8.1 INCREASING USE OF HIGH-CONTENT SCREENING, MICROSCOPY, AND PHENOTYPIC ASSAYS EXPANDS APPLICATIONS
10.9 PHYSICS-BASED & HYBRID AI METHODS
10.9.1 NEED FOR MECHANISTIC UNDERSTANDING AND IMPROVED ACCURACY IN MOLECULAR MODELING DRIVES SEGMENT
11 AI IN DRUG DISCOVERY MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 GROWING PRESSURE TO ACCELERATE R&D PRODUCTIVITY AND REDUCE DRUG DISCOVERY COSTS DRIVES SEGMENT
11.2.2 LARGE PHARMACEUTICAL COMPANIES
11.2.2.1 High R&D expenditure and increasing need to improve pipeline productivity accelerate AI adoption
11.2.3 SMALL & MID-SIZED BIOTECHNOLOGY COMPANIES
11.2.3.1 Limited internal resources and need for differentiated pipelines increase reliance on AI-enabled discovery
11.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CDMOS
11.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY ACTIVITIES DRIVES GROWTH
11.4 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS
11.4.1 GROWING AVAILABILITY OF RESEARCH FUNDING AND ADVANCED AI CAPABILITIES EXPANDS GROWTH
12 AI IN DRUG DISCOVERY MARKET, BY USE CASE
12.1 INTRODUCTION
12.2 UNDERSTANDING DISEASE BIOLOGY
12.2.1 INCREASED FOCUS ON UNDERSTANDING DISEASES TO IMPROVE RESEARCH DATA QUALITY AND QUANTITY
12.2.2 EVIDENCE SYNTHESIS AND SCIENTIFIC LITERATURE INTELLIGENCE
12.2.2.1 Rapid data analysis – key demand driver
12.2.3 MULTIOMICS INTEGRATION & TARGET-DISEASE ASSOCIATION
12.2.3.1 Growing integration of genomic, transcriptomic, proteomic, metabolomic, and other biological datasets to drive market
12.2.4 EXPERIMENT DESIGN & REAGENT/MODEL SELECTION
12.2.4.1 Growing complexity of disease biology and experiment design boosts demand
12.3 PROTEIN STRUCTURE & INTERACTION PREDICTION
12.3.1 ADVANCES IN AI-POWERED PROTEIN INTERACTION PREDICTION ACCELERATE STRUCTURE-BASED DRUG DISCOVERY
12.4 DRUG REPURPOSING
12.4.1 INCREASING ADOPTION OF AI PLATFORMS FOR SYSTEMATIC DRUG REPURPOSING
12.5 DE NOVO DRUG DESIGN
12.5.1 SMALL MOLECULE DESIGN
12.5.1.1 Increasing use of virtual screening and simulation techniques to drive growth
12.5.2 VACCINE DESIGN
12.5.2.1 Availability of well-validated AI tools to boost market growth
12.5.3 ANTIBODY & OTHER BIOLOGICS DESIGN
12.5.3.1 Advancements in protein modeling to propel segment growth
12.5.4 PROTEIN & ENZYME DESIGN
12.5.4.1 Protein designing to propel segment growth
12.6 DRUG OPTIMIZATION
12.6.1 SMALL MOLECULE OPTIMIZATION
12.6.1.1 Generative models for potential modifications in molecular structures to aid market growth
12.6.2 VACCINE OPTIMIZATION
12.6.2.1 Effective prediction of vaccine formulations and adjustment of delivery vectors to drive growth
12.6.3 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION
12.6.3.1 Increasing adoption of machine learning to predict protein structures to augment segment growth
12.7 SAFETY & TOXICITY
12.7.1 FOCUS ON ADVANCED OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO DRIVE MARKET
13 AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT
13.1 INTRODUCTION
13.2 ON-PREMISE SOLUTIONS
13.2.1 GROWING DEMAND FOR DATA SOVEREIGNTY, IP PROTECTION, AND CONTROL OVER PROPRIETARY R&D DATA SUPPORTS GROWTH DEPLOYMENT
13.3 CLOUD-BASED SOLUTIONS
13.3.1 NEED FOR SCALABLE COMPUTING, RAPID AI DEPLOYMENT, AND COST-EFFICIENT ACCESS TO ADVANCED INFRASTRUCTURE - KEY DRIVERS
13.3.2 PUBLIC CLOUD
13.3.2.1 Elastic computing capacity and access to advanced AI infrastructure drive adoption
13.3.3 PRIVATE CLOUD/VPC/SOVEREIGN DEPLOYMENT
13.3.3.1 Increasing data-security, IP-protection, and data-residency requirements strengthen demand
13.4 HYBRID SOLUTIONS
13.4.1 NEED TO BALANCE COMPUTATIONAL SCALABILITY WITH CONTROL OVER SENSITIVE R&D DATA ACCELERATES ADOPTION
14 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
14.1 INTRODUCTION
14.2 ONCOLOGY
14.2.1 HIGH PREVALENCE OF ONCOLOGY AND SHORTAGE OF EFFECTIVE ONCOLOGY DRUGS TO DRIVE MARKET GROWTH
14.3 INFECTIOUS DISEASES
14.3.1 RISING ANTIMICROBIAL RESISTANCE AND NEED FOR NOVEL ANTI-INFECTIVE THERAPIES TO DRIVE GROWTH
14.4 NEUROLOGY
14.4.1 HIGH DISEASE COMPLEXITY AND LIMITED TREATMENT OPTIONS DRIVE DEMAND FOR AI-ENABLED DISCOVERY
14.5 CARDIOVASCULAR DISEASES
14.5.1 GROWING CARDIOVASCULAR DISEASE BURDEN AND NEED FOR NOVEL THERAPEUTIC TARGETS BOOST GROWTH
14.6 METABOLIC DISEASES
14.6.1 RISING PREVALENCE OF OBESITY AND METABOLIC DISORDERS ACCELERATES DEMAND FOR INNOVATIVE THERAPIES
14.7 IMMUNOLOGY
14.7.1 COMPLEX IMMUNE MECHANISMS AND GROWING DEMAND FOR TARGETED THERAPIES DRIVE AI ADOPTION
14.8 RARE & GENETIC DISORDERS
14.8.1 LIMITED TREATMENT OPTIONS AND FRAGMENTED DISEASE DATA DRIVE AI-ENABLED DRUG DISCOVERY
14.9 MENTAL HEALTH DISORDERS
14.9.1 HIGH UNMET NEED AND LIMITED UNDERSTANDING OF DISEASE MECHANISMS DRIVE SEGMENT GROWTH
14.10 OTHER THERAPEUTIC AREAS
14.10.1 EXPANDING APPLICATION OF AI ACROSS UNDEREXPLORED DISEASE AREAS DRIVES MARKET GROWTH
15 AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE
15.1 INTRODUCTION
15.2 END-TO-END SOLUTION PROVIDERS
15.2.1 INCREASING ADOPTION OF INTEGRATED AI PLATFORMS ACROSS DRUG DISCOVERY WORKFLOW DRIVES GROWTH
15.3 NICHE/POINT SOLUTION PROVIDERS
15.3.1 GROWING DEMAND FOR SPECIALIZED AI CAPABILITIES TARGETING COMPLEX DISCOVERY CHALLENGES TO DRIVE GROWTH
15.4 AI TECHNOLOGY PROVIDERS
15.4.1 RAPID ADVANCES IN GENERATIVE AI, FOUNDATION MODELS, AND AGENTIC AI ACCELERATE DEMAND
15.5 COMPUTE & INFRASTRUCTURE PROVIDERS
15.5.1 GROWING COMPUTATIONAL REQUIREMENTS OF ADVANCED AI MODELS DRIVE DEMAND
15.6 BUSINESS PROCESS SERVICE PROVIDERS
15.6.1 INCREASING OUTSOURCING OF SPECIALIZED AI-ENABLED DISCOVERY ACTIVITIES DRIVES GROWTH
16 AI IN DRUG DISCOVERY MARKET, BY REGION
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
16.2.2 US
16.2.2.1 Strong pharma–AI ecosystem and high R&D investment drives demand
16.2.3 CANADA
16.2.3.1 Strong AI research base and growing biopharma innovation – key drivers
16.3 EUROPE
16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
16.3.2 GERMANY
16.3.2.1 Availability of advanced computing and research infrastructure – key market driver
16.3.3 UK
16.3.3.1 Increasing investment in AI-based molecular design drives demand
16.3.4 SWITZERLAND
16.3.4.1 Strong pharmaceutical and biotechnology ecosystem to boost market
16.3.5 FRANCE
16.3.5.1 Large-scale AI investment by pharmaceutical companies – key driver
16.3.6 ITALY
16.3.6.1 Market driven by country’s strong pharmaceutical and life sciences ecosystem
16.3.7 SPAIN
16.3.7.1 Expansion of AI-enabled biotechnology research drives demand
16.3.8 REST OF EUROPE
16.3.8.1 Growing pharmaceutical R&D and public-sector AI adoption to drive market
16.4 ASIA PACIFIC
16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
16.4.2 JAPAN
16.4.2.1 Increasing pharmaceutical investment in AI and robotics drives demand
16.4.3 CHINA
16.4.3.1 Growth of AI-native biotech companies boosts demand
16.4.4 INDIA
16.4.4.1 Large pharmaceutical and biotechnology ecosystem to propel market
16.4.5 SOUTH KOREA
16.4.5.1 Government support for AI-based drug discovery to boost market
16.4.6 AUSTRALIA
16.4.6.1 Market driven by strong government support for AI and medical research
16.4.7 REST OF ASIA PACIFIC
16.4.7.1 Growth of regional pharmaceutical and biotechnology capabilities to boost market
16.5 LATIN AMERICA
16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
16.5.2 BRAZIL
16.5.2.1 Expanding pharmaceutical R&D and emerging AI-biotech ecosystem act as major drivers
16.5.3 MEXICO
16.5.3.1 Multinational pharmaceutical activity and government-backed research to drive market
16.5.4 REST OF LATIN AMERICA
16.5.4.1 Growing research base for AI to drive market
16.6 MIDDLE EAST & AFRICA
16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
16.6.2 GCC COUNTRIES
16.6.2.1 National AI strategies and growing technology partnerships act as major drivers
16.6.3 SAUDI ARABIA
16.6.3.1 Government investment in biotechnology and life sciences propels market
16.6.4 UAE
16.6.4.1 Government-led AI and biotechnology investment boosts market
16.6.5 REST OF GCC
16.6.5.1 International AI-drug discovery partnerships drive demand
16.6.6 SOUTH AFRICA
16.6.6.1 Strong domestic drug-discovery research base drives market
16.6.7 REST OF MIDDLE EAST & AFRICA
16.6.7.1 Expansion of local pharmaceutical and biomanufacturing capabilities drives demand
17 COMPETITIVE LANDSCAPE
17.1 OVERVIEW
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET
17.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
17.4 MARKET SHARE ANALYSIS, 2025
17.5 BRAND COMPARISON
17.6 VALUATION & FINANCIAL METRICS
17.6.1 FINANCIAL METRICS
17.6.2 COMPANY VALUATION
17.7 COMPANY EVALUATION MATRIX
17.7.1 STARS
17.7.2 EMERGING LEADERS
17.7.3 PERVASIVE PLAYERS
17.7.4 PARTICIPANTS
17.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
17.7.5.1 Company footprint
17.7.5.2 Region footprint
17.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.8.1 PROGRESSIVE COMPANIES
17.8.2 RESPONSIVE COMPANIES
17.8.3 DYNAMIC COMPANIES
17.8.4 STARTING BLOCKS
17.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
17.8.5.1 Detailed list of key startups/SMEs
17.8.5.2 Competitive benchmarking of startups/SMEs
17.9 COMPETITIVE SCENARIO
17.9.1 PRODUCT/SERVICE LAUNCHES
17.9.2 DEALS
17.9.3 EXPANSIONS
17.9.4 OTHER DEVELOPMENTS
18 COMPANY PROFILES
18.1 KEY PLAYERS
18.1.1 NVIDIA CORPORATION
18.1.1.1 Business overview
18.1.1.2 Products/Services offered
18.1.1.3 Recent developments
18.1.1.3.1 Product/Service launches & approvals
18.1.1.3.2 Deals
18.1.1.3.3 Other developments
18.1.1.4 MnM view
18.1.1.4.1 Right to win
18.1.1.4.2 Strategic choices
18.1.1.4.3 Weaknesses & competitive threats
18.1.2 ALPHABET INC.
18.1.2.1 Business overview
18.1.2.2 Products/Services offered
18.1.2.3 Recent developments
18.1.2.3.1 Product launches & approvals
18.1.2.3.2 Deals
18.1.2.3.3 Other developments
18.1.2.4 MnM view
18.1.2.4.1 Right to win
18.1.2.4.2 Strategic choices
18.1.2.4.3 Weaknesses & competitive threats
18.1.3 RECURSION
18.1.3.1 Business overview
18.1.3.2 Products/Services offered
18.1.3.3 Recent developments
18.1.3.3.1 Product/Service launches
18.1.3.3.2 Deals
18.1.3.3.3 Expansions
18.1.3.4 MnM view
18.1.3.4.1 Right to win
18.1.3.4.2 Strategic choices
18.1.3.4.3 Weaknesses & competitive threats
18.1.4 INSILICO MEDICINE
18.1.4.1 Business overview
18.1.4.2 Products/Services offered
18.1.4.3 Recent developments
18.1.4.3.1 Product/Service launches
18.1.4.3.2 Deals
18.1.4.3.3 Other developments
18.1.4.3.4 expansions
18.1.4.4 MnM view
18.1.4.4.1 Right to win
18.1.4.4.2 Strategic choices
18.1.4.4.3 Weaknesses & competitive threats
18.1.5 SCHR?DINGER, INC.
18.1.5.1 Business overview
18.1.5.2 Products/Services offered
18.1.5.3 Recent developments
18.1.5.3.1 Deals
18.1.5.3.2 Other developments
18.1.5.4 MnM view
18.1.5.4.1 Right to win
18.1.5.4.2 Strategic choices
18.1.5.4.3 Weaknesses & competitive threats
18.1.6 BENEVOLENTAI
18.1.6.1 Business overview
18.1.6.2 Products/Services offered
18.1.6.3 Recent developments
18.1.6.3.1 Deals
18.1.7 MICROSOFT CORPORATION
18.1.7.1 Business overview
18.1.7.2 Products /Services offered
18.1.7.3 Recent developments
18.1.7.3.1 Product/Service launches & approvals
18.1.7.3.2 Deals
18.1.8 NUMERION LABS
18.1.8.1 Business overview
18.1.8.2 Products/Services offered
18.1.9 ILLUMINA, INC.
18.1.9.1 Business overview
18.1.9.2 Products/Services offered
18.1.9.3 Recent developments
18.1.9.3.1 Product/Service launches
18.1.9.3.2 Deals
18.1.10 XTALPI INC.
18.1.10.1 Business overview
18.1.10.2 Products/Services offered
18.1.10.3 Recent developments
18.1.10.3.1 Deals
18.1.11 IKTOS
18.1.11.1 Business overview
18.1.11.2 Products/Services offered
18.1.11.3 Recent developments
18.1.11.3.1 Deals
18.1.11.3.2 Other developments
18.1.12 TEMPUS AI, INC.
18.1.12.1 Business overview
18.1.12.2 Products/Services offered
18.1.12.3 Recent developments
18.1.12.3.1 Product/Service launches
18.1.12.3.2 Deals
18.1.13 DEEP GENOMICS, INC.
18.1.13.1 Business overview
18.1.13.2 Products/Services offered
18.1.13.3 Recent developments
18.1.13.3.1 Product/Service launches & approvals
18.1.14 VERGE LABS
18.1.14.1 Business overview
18.1.14.2 Products /Services offered
18.1.14.3 Recent developments
18.1.14.3.1 Deals
18.1.15 BENCHSCI
18.1.15.1 Business overview
18.1.15.2 Products/Services offered
18.1.15.3 Recent developments
18.1.15.3.1 Product/Service launches & approvals
18.1.15.3.2 Deals
18.1.15.3.3 Other developments
18.1.16 INSITRO
18.1.16.1 Business overview
18.1.16.2 Products/Services offered
18.1.16.3 Recent developments
18.1.16.3.1 Deals
18.1.16.3.2 Other developments
18.1.17 VALO HEALTH
18.1.17.1 Business overview
18.1.17.2 Products/Services offered
18.1.17.3 Recent developments
18.1.17.3.1 Deals
18.1.17.3.2 Other developments
18.1.18 BPGBIO, INC.
18.1.18.1 Business overview
18.1.18.2 Products/Services offered
18.1.18.3 Recent developments
18.1.18.3.1 Deals
18.1.19 GENERATE:BIOMEDICINES
18.1.19.1 Business overview
18.1.19.2 Products/Services offered
18.1.19.3 Recent developments
18.1.19.3.1 Product/Service launches
18.1.19.3.2 Deals
18.1.19.3.3 Expansions
18.1.20 CERTARA, INC.
18.1.20.1 Business overview
18.1.20.2 Products/Services offered
18.1.20.3 Recent developments
18.1.20.3.1 Product/Service launches & approvals
18.1.20.3.2 Deals
18.2 OTHER EMERGING PLAYERS
18.2.1 XAIRA THERAPEUTICS
18.2.2 IAMBIC THERAPEUTICS, INC.
18.2.3 GENESIS MOLECULAR AI
18.2.4 CRADLE BIO
18.2.5 ISOMORPHIC LABS
19 RESEARCH METHODOLOGY
19.1 RESEARCH APPROACH
19.1.1 SECONDARY RESEARCH
19.1.1.1 Key data from secondary sources
19.1.2 PRIMARY RESEARCH
19.1.2.1 Primary sources
19.1.2.2 Key data from primary sources
19.1.2.3 Breakdown of primaries
19.1.2.4 Insights from primary experts
19.2 RESEARCH METHODOLOGY DESIGN
19.3 MARKET SIZE ESTIMATION
19.4 MARKET BREAKDOWN DATA TRIANGULATION
19.5 MARKET SHARE ESTIMATION
19.6 STUDY ASSUMPTIONS
19.7 RESEARCH LIMITATIONS
19.7.1 METHODOLOGY-RELATED LIMITATIONS
19.8 RISK ASSESSMENT
20 APPENDIX
20.1 DISCUSSION GUIDE
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3 CUSTOMIZATION OPTIONS
20.4 RELATED REPORTS
20.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 USD EXCHANGE RATES
TABLE 2 AI IN DRUG DISCOVERY: COLLABORATIONS AND PARTNERSHIPS, 2024–2026
TABLE 3 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2025 AND 2026
TABLE 4 AI IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM
TABLE 5 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY PLATFORMS, BY KEY PLAYERS, 2025
TABLE 6 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY MARKET, BY REGION (2025)
TABLE 7 KEY CONFERENCES & EVENTS IN AI IN DRUG DISCOVERY MARKET, JULY 2026-JUNE 2027
TABLE 8 CASE 1: TERRAY THERAPEUTICS’ USE OF NVIDIA TO ACCELERATE GENERATIVE AI-ENABLED SMALL-MOLECULE DRUG DISCOVERY
TABLE 9 CASE 2: ASTELLAS PHARMA’S USE OF NVIDIA AI TO ACCELERATE BIOMOLECULAR DISCOVERY AND COMPOUND SCREENING
TABLE 10 CASE 3: AMGEN–NVIDIA COLLABORATION ACCELERATES BIOLOGICS DISCOVERY THROUGH GENERATIVE AI
TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 12 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN DRUG DISCOVERY
TABLE 13 AI IN DRUG DISCOVERY MARKET: KEY PATENTS/PATENT APPLICATIONS
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 REGULATORY SCENARIO OF NORTH AMERICA
TABLE 20 REGULATORY SCENARIO OF EUROPE
TABLE 21 REGULATORY SCENARIO OF ASIA PACIFIC
TABLE 22 REGULATORY SCENARIO OF LATIN AMERICA
TABLE 23 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
TABLE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 26 AI IN DRUG DISCOVERY MARKET: UNMET NEEDS
TABLE 27 DRUG DISCOVERY MARKET: END USER EXPECTATIONS
TABLE 28 AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 29 AI IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 AI IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 31 AI IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 AI IN DRUG DISCOVERY MARKET FOR HIT TO LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 AI IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 AI IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 36 MACHINE LEARNING: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 37 MACHINE LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 38 DEEP LEARNING: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 39 DEEP LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 TRANSFORMER-BASED ARCHITECTURE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 GRAPH NEURAL NETWORKS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 CONVOLUTIONAL NEURAL NETWORKS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 DIFFUSION AND FLOW-BASED MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 GAN & VAE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 RECURRENT & SEQUENCE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 OTHER DEEP LEARNING TECHNOLOGIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 47 SUPERVISED LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 SELF-SUPERVISED & REPRESENTATION LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 REINFORCEMENT LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 UNSUPERVISED LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 OTHER MACHINE LEARNING TECHNOLOGIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 52 GENERATIVE AI: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 53 GENERATIVE AI: AI IN DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
TABLE 54 MOLECULAR GENERATIVE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 PROTEIN & BIOLOGICS GENERATIVE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 LARGE LANGUAGE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 58 FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 59 CHEMISTRY FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 60 PROTEIN LANGUAGE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 BIOLOGY AND MULTIOMICS FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 AGENTIC AI & CO-SCIENTISTS: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 63 AGENTIC AI & CO-SCIENTISTS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 AUTONOMOUS RESEARCH AGENTS & WORKFLOW ORCHESTRATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 MULTI-AGENT REASONING SYSTEMS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 LAB-IN-THE-LOOP & CLOSED-LOOP EXPERIMENTATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 67 KNOWLEDGE GRAPHS AND SEMANTIC REASONING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 68 NATURAL LANGUAGE PROCESSING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 COMPUTER VISION & IMAGE ANALYSIS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 PHYSICS-BASED & HYBRID AI MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 73 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 LARGE PHARMACEUTICAL COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 SMALL & MID-SIZED BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 CROS & CDMOS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 78 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 79 UNDERSTANDING DISEASE BIOLOGY: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 80 UNDERSTANDING DISEASE BIOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 EVIDENCE SYNTHESIS AND SCIENTIFIC LITERATURE INTELLIGENCE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 MULTIOMICS INTEGRATION & TARGET DISEASE ASSOCIATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 83 EXPERIMENT DESIGN & REAGENT/MODEL SELECTION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 PROTEIN STRUCTURE & INTERACTION PREDICTION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 DRUG REPURPOSING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 86 DE NOVO DRUG DESIGN: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 87 DE NOVO DRUG DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 88 SMALL MOLECULE DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 VACCINE DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 ANTIBODY & OTHER BIOLOGICS DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 PROTEIN & ENZYME DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 92 DRUG OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 93 DRUG OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 SMALL MOLECULE OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 VACCINE OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 SAFETY & TOXICITY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 98 AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 99 ON-PREMISE SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 100 CLOUD-BASED SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 101 CLOUD-BASED SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 PUBLIC DEPLOYMENT: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 PRIVATE CLOUD/VPC/SOVEREIGN DEPLOYMENT: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 104 HYBRID SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 106 ONCOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 INFECTIOUS DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NEUROLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 109 CARDIOVASCULAR DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 METABOLIC DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 111 IMMUNOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 RARE & GENETIC DISORDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 MENTAL DISORDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 114 OTHER THERAPEUTIC AREAS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 116 END-TO-END SOLUTION PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 NICHE/POINT SOLUTION PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 118 AI TECHNOLOGY PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 COMPUTE & INFRASTRUCTURE PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 BUSINESS PROCESS SERVICE PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 122 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 124 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 125 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 129 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 130 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 131 NORTH AMERICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 132 NORTH AMERICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 135 NORTH AMERICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 136 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 137 NORTH AMERICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 139 NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 140 US: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 141 US: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 142 US: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143 US: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 144 US: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 145 US: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 146 US: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 147 US: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 148 US: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 149 US: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150 US: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151 US: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 US: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 153 US: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 154 US: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 155 US: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 156 US: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 157 CANADA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 158 CANADA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 159 CANADA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 CANADA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161 CANADA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 CANADA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 163 CANADA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 164 CANADA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 165 CANADA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 166 CANADA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167 CANADA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 CANADA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 169 CANADA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 170 CANADA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 171 CANADA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172 CANADA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 173 CANADA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 174 EUROPE: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 EUROPE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 176 EUROPE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 177 EUROPE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 EUROPE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 180 EUROPE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 182 EUROPE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 183 EUROPE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 184 EUROPE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 185 EUROPE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 189 EUROPE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 190 EUROPE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 191 EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192 GERMANY: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 193 GERMANY: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 194 GERMANY: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 GERMANY: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 GERMANY: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197 GERMANY: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 198 GERMANY: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 199 GERMANY: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 200 GERMANY: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 201 GERMANY: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202 GERMANY: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203 GERMANY: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 204 GERMANY: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 205 GERMANY: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 206 GERMANY: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 207 GERMANY: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 208 GERMANY: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209 UK: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 210 UK: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 211 UK: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 UK: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 UK: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 214 UK: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 215 UK: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 216 UK: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 217 UK: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218 UK: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 219 UK: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 220 UK: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 221 UK: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222 UK: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 223 UK: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 224 UK: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 225 UK: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 227 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 228 SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 229 SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230 SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 232 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 233 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 234 SWITZERLAND: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 235 SWITZERLAND: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 SWITZERLAND: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 237 SWITZERLAND: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 SWITZERLAND: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 240 SWITZERLAND: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 241 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 242 SWITZERLAND: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 243 FRANCE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 244 FRANCE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 245 FRANCE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 246 FRANCE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 247 FRANCE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 248 FRANCE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 249 FRANCE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 250 FRANCE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 251 FRANCE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 252 FRANCE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253 FRANCE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 254 FRANCE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 255 FRANCE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 256 FRANCE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 257 FRANCE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 FRANCE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 259 FRANCE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 260 ITALY: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 261 ITALY: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 262 ITALY: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 263 ITALY: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 264 ITALY: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 265 ITALY: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 266 ITALY: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 267 ITALY: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 268 ITALY: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269 ITALY: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 270 ITALY: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 271 ITALY: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 272 ITALY: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 273 ITALY: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 274 ITALY: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 275 ITALY: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 276 ITALY: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 277 SPAIN: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 278 SPAIN: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 279 SPAIN: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280 SPAIN: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 281 SPAIN: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 282 SPAIN: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 283 SPAIN: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 284 SPAIN: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 285 SPAIN: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 286 SPAIN: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287 SPAIN: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288 SPAIN: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 289 SPAIN: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 290 SPAIN: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 291 SPAIN: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 292 SPAIN: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 293 SPAIN: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 294 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 295 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 296 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 299 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 300 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 301 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 302 REST OF EUROPE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 303 REST OF EUROPE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 304 REST OF EUROPE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 305 REST OF EUROPE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 306 REST OF EUROPE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 307 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 308 REST OF EUROPE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 309 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 310 REST OF EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 311 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 313 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 314 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 315 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 316 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 317 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 318 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 319 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 320 ASIA PACIFIC: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321 ASIA PACIFIC: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 322 ASIA PACIFIC: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 323 ASIA PACIFIC: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 324 ASIA PACIFIC: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 325 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 326 ASIA PACIFIC: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 327 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 1 USD EXCHANGE RATES
TABLE 2 AI IN DRUG DISCOVERY: COLLABORATIONS AND PARTNERSHIPS, 2024–2026
TABLE 3 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2025 AND 2026
TABLE 4 AI IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM
TABLE 5 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY PLATFORMS, BY KEY PLAYERS, 2025
TABLE 6 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY MARKET, BY REGION (2025)
TABLE 7 KEY CONFERENCES & EVENTS IN AI IN DRUG DISCOVERY MARKET, JULY 2026-JUNE 2027
TABLE 8 CASE 1: TERRAY THERAPEUTICS’ USE OF NVIDIA TO ACCELERATE GENERATIVE AI-ENABLED SMALL-MOLECULE DRUG DISCOVERY
TABLE 9 CASE 2: ASTELLAS PHARMA’S USE OF NVIDIA AI TO ACCELERATE BIOMOLECULAR DISCOVERY AND COMPOUND SCREENING
TABLE 10 CASE 3: AMGEN–NVIDIA COLLABORATION ACCELERATES BIOLOGICS DISCOVERY THROUGH GENERATIVE AI
TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 12 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN DRUG DISCOVERY
TABLE 13 AI IN DRUG DISCOVERY MARKET: KEY PATENTS/PATENT APPLICATIONS
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 REGULATORY SCENARIO OF NORTH AMERICA
TABLE 20 REGULATORY SCENARIO OF EUROPE
TABLE 21 REGULATORY SCENARIO OF ASIA PACIFIC
TABLE 22 REGULATORY SCENARIO OF LATIN AMERICA
TABLE 23 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
TABLE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 26 AI IN DRUG DISCOVERY MARKET: UNMET NEEDS
TABLE 27 DRUG DISCOVERY MARKET: END USER EXPECTATIONS
TABLE 28 AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 29 AI IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 AI IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 31 AI IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 32 AI IN DRUG DISCOVERY MARKET FOR HIT TO LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 AI IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 34 AI IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 36 MACHINE LEARNING: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 37 MACHINE LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 38 DEEP LEARNING: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 39 DEEP LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 40 TRANSFORMER-BASED ARCHITECTURE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 41 GRAPH NEURAL NETWORKS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 CONVOLUTIONAL NEURAL NETWORKS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 DIFFUSION AND FLOW-BASED MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 44 GAN & VAE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 RECURRENT & SEQUENCE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 OTHER DEEP LEARNING TECHNOLOGIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 47 SUPERVISED LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48 SELF-SUPERVISED & REPRESENTATION LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 REINFORCEMENT LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 50 UNSUPERVISED LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 OTHER MACHINE LEARNING TECHNOLOGIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 52 GENERATIVE AI: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 53 GENERATIVE AI: AI IN DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
TABLE 54 MOLECULAR GENERATIVE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 PROTEIN & BIOLOGICS GENERATIVE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 LARGE LANGUAGE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 58 FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 59 CHEMISTRY FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 60 PROTEIN LANGUAGE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61 BIOLOGY AND MULTIOMICS FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 AGENTIC AI & CO-SCIENTISTS: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 63 AGENTIC AI & CO-SCIENTISTS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 AUTONOMOUS RESEARCH AGENTS & WORKFLOW ORCHESTRATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 MULTI-AGENT REASONING SYSTEMS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 66 LAB-IN-THE-LOOP & CLOSED-LOOP EXPERIMENTATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 67 KNOWLEDGE GRAPHS AND SEMANTIC REASONING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 68 NATURAL LANGUAGE PROCESSING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 COMPUTER VISION & IMAGE ANALYSIS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 PHYSICS-BASED & HYBRID AI MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 73 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 LARGE PHARMACEUTICAL COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 SMALL & MID-SIZED BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 CROS & CDMOS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 77 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 78 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 79 UNDERSTANDING DISEASE BIOLOGY: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 80 UNDERSTANDING DISEASE BIOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 EVIDENCE SYNTHESIS AND SCIENTIFIC LITERATURE INTELLIGENCE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 MULTIOMICS INTEGRATION & TARGET DISEASE ASSOCIATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 83 EXPERIMENT DESIGN & REAGENT/MODEL SELECTION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 PROTEIN STRUCTURE & INTERACTION PREDICTION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85 DRUG REPURPOSING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 86 DE NOVO DRUG DESIGN: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 87 DE NOVO DRUG DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 88 SMALL MOLECULE DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 VACCINE DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 ANTIBODY & OTHER BIOLOGICS DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 91 PROTEIN & ENZYME DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 92 DRUG OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 93 DRUG OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 SMALL MOLECULE OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 VACCINE OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 97 SAFETY & TOXICITY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 98 AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 99 ON-PREMISE SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 100 CLOUD-BASED SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 101 CLOUD-BASED SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 PUBLIC DEPLOYMENT: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 103 PRIVATE CLOUD/VPC/SOVEREIGN DEPLOYMENT: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 104 HYBRID SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 105 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 106 ONCOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 INFECTIOUS DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NEUROLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 109 CARDIOVASCULAR DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 110 METABOLIC DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 111 IMMUNOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 112 RARE & GENETIC DISORDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 MENTAL DISORDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 114 OTHER THERAPEUTIC AREAS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 115 AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 116 END-TO-END SOLUTION PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 NICHE/POINT SOLUTION PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 118 AI TECHNOLOGY PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 COMPUTE & INFRASTRUCTURE PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 BUSINESS PROCESS SERVICE PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 122 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 124 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 125 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 129 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 130 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 131 NORTH AMERICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 132 NORTH AMERICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 135 NORTH AMERICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 136 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 137 NORTH AMERICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 139 NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 140 US: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 141 US: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 142 US: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143 US: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 144 US: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 145 US: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 146 US: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 147 US: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 148 US: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 149 US: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150 US: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151 US: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 US: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 153 US: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 154 US: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 155 US: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 156 US: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 157 CANADA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 158 CANADA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 159 CANADA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 CANADA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161 CANADA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162 CANADA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 163 CANADA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 164 CANADA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 165 CANADA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 166 CANADA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167 CANADA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168 CANADA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 169 CANADA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 170 CANADA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 171 CANADA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172 CANADA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 173 CANADA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 174 EUROPE: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 EUROPE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 176 EUROPE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 177 EUROPE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 EUROPE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 180 EUROPE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 182 EUROPE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 183 EUROPE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 184 EUROPE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 185 EUROPE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 188 EUROPE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 189 EUROPE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 190 EUROPE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 191 EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192 GERMANY: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 193 GERMANY: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 194 GERMANY: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 GERMANY: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 GERMANY: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197 GERMANY: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 198 GERMANY: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 199 GERMANY: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 200 GERMANY: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 201 GERMANY: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202 GERMANY: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 203 GERMANY: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 204 GERMANY: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 205 GERMANY: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 206 GERMANY: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 207 GERMANY: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 208 GERMANY: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 209 UK: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 210 UK: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 211 UK: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 UK: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 UK: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 214 UK: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 215 UK: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 216 UK: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 217 UK: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218 UK: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 219 UK: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 220 UK: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 221 UK: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222 UK: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 223 UK: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 224 UK: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 225 UK: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 227 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 228 SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 229 SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 230 SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 232 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 233 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 234 SWITZERLAND: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 235 SWITZERLAND: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 236 SWITZERLAND: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 237 SWITZERLAND: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 SWITZERLAND: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 240 SWITZERLAND: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 241 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 242 SWITZERLAND: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 243 FRANCE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 244 FRANCE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 245 FRANCE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 246 FRANCE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 247 FRANCE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 248 FRANCE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 249 FRANCE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 250 FRANCE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 251 FRANCE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 252 FRANCE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 253 FRANCE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 254 FRANCE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 255 FRANCE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 256 FRANCE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 257 FRANCE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258 FRANCE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 259 FRANCE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 260 ITALY: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 261 ITALY: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 262 ITALY: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 263 ITALY: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 264 ITALY: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 265 ITALY: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 266 ITALY: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 267 ITALY: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 268 ITALY: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269 ITALY: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 270 ITALY: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 271 ITALY: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 272 ITALY: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 273 ITALY: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 274 ITALY: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 275 ITALY: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 276 ITALY: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 277 SPAIN: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 278 SPAIN: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 279 SPAIN: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280 SPAIN: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 281 SPAIN: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 282 SPAIN: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 283 SPAIN: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 284 SPAIN: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 285 SPAIN: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 286 SPAIN: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287 SPAIN: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288 SPAIN: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 289 SPAIN: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 290 SPAIN: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 291 SPAIN: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 292 SPAIN: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 293 SPAIN: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 294 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 295 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 296 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 299 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 300 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 301 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 302 REST OF EUROPE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 303 REST OF EUROPE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 304 REST OF EUROPE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 305 REST OF EUROPE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 306 REST OF EUROPE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 307 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 308 REST OF EUROPE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 309 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 310 REST OF EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 311 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION)
TABLE 313 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION)
TABLE 314 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 315 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION)
TABLE 316 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION)
TABLE 317 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 318 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION)
TABLE 319 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION)
TABLE 320 ASIA PACIFIC: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321 ASIA PACIFIC: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 322 ASIA PACIFIC: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 323 ASIA PACIFIC: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 324 ASIA PACIFIC: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 325 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION)
TABLE 326 ASIA PACIFIC: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 327 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 AI IN DRUG DISCOVERY MARKET SEGMENTATION
FIGURE 2 REGIONAL SCOPE
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL AI IN DRUG DISCOVERY MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET, 2023–2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF AI IN DRUG DISCOVERY MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN AI IN DRUG DISCOVERY MARKET, 2026–2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD
FIGURE 9 RISING DEMAND FOR AI IN DRUG DISCOVERY AND REDUCED DRUG DEVELOPMENT COSTS TO DRIVE MARKET GROWTH
FIGURE 10 CLOUD-BASED SOLUTIONS AND US ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
FIGURE 11 JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ENVIRONMENTAL MONITORING MARKET
FIGURE 13 APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2020–2024
FIGURE 14 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS
FIGURE 16 AI IN DRUG DISCOVERY MARKET: ECOSYSTEM ANALYSIS
FIGURE 17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 19 PATENT PUBLICATION TRENDS IN AI IN DRUG DISCOVERY MARKET, 2015–2026
FIGURE 20 JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN DRUG DISCOVERY MARKET
FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN DRUG DISCOVERY MARKET (JANUARY 2015 TO AUGUST 2026)
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 24 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET SNAPSHOT
FIGURE 25 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET SNAPSHOT
FIGURE 26 AI IN DRUG DISCOVERY MARKET: REVENUE ANALYSIS OF KEY PLAYERS
FIGURE 27 AI IN DRUG DISCOVERY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 28 AI IN DRUG DISCOVERY MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 29 EV/EBITDA OF KEY VENDORS
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 31 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX, KEY PLAYERS (2025)
FIGURE 32 AI IN DRUG DISCOVERY MARKET: COMPANY FOOTPRINT
FIGURE 33 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 34 NVIDIA CORPORATION: COMPANY SNAPSHOT (2026)
FIGURE 35 ALPHABET INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 RECURSION: COMPANY SNAPSHOT (2025)
FIGURE 37 INSILICO MEDICINE: COMPANY SNAPSHOT (2025)
FIGURE 38 SCHR?DINGER, INC.: COMPANY SNAPSHOT (2025)
FIGURE 39 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2026)
FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 41 XTALPI INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
FIGURE 43 CERTARA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 44 RESEARCH DESIGN
FIGURE 45 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 46 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 47 BOTTOM-UP APPROACH
FIGURE 48 TOP-DOWN APPROACH
FIGURE 49 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AI IN DRUG DISCOVERY INDUSTRY
FIGURE 50 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 51 DATA TRIANGULATION METHODOLOGY
FIGURE 1 AI IN DRUG DISCOVERY MARKET SEGMENTATION
FIGURE 2 REGIONAL SCOPE
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL AI IN DRUG DISCOVERY MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET, 2023–2026
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF AI IN DRUG DISCOVERY MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS IN AI IN DRUG DISCOVERY MARKET, 2026–2031
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD
FIGURE 9 RISING DEMAND FOR AI IN DRUG DISCOVERY AND REDUCED DRUG DEVELOPMENT COSTS TO DRIVE MARKET GROWTH
FIGURE 10 CLOUD-BASED SOLUTIONS AND US ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
FIGURE 11 JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ENVIRONMENTAL MONITORING MARKET
FIGURE 13 APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2020–2024
FIGURE 14 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS
FIGURE 16 AI IN DRUG DISCOVERY MARKET: ECOSYSTEM ANALYSIS
FIGURE 17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 19 PATENT PUBLICATION TRENDS IN AI IN DRUG DISCOVERY MARKET, 2015–2026
FIGURE 20 JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN DRUG DISCOVERY MARKET
FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN DRUG DISCOVERY MARKET (JANUARY 2015 TO AUGUST 2026)
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 24 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET SNAPSHOT
FIGURE 25 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET SNAPSHOT
FIGURE 26 AI IN DRUG DISCOVERY MARKET: REVENUE ANALYSIS OF KEY PLAYERS
FIGURE 27 AI IN DRUG DISCOVERY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
FIGURE 28 AI IN DRUG DISCOVERY MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 29 EV/EBITDA OF KEY VENDORS
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 31 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX, KEY PLAYERS (2025)
FIGURE 32 AI IN DRUG DISCOVERY MARKET: COMPANY FOOTPRINT
FIGURE 33 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 34 NVIDIA CORPORATION: COMPANY SNAPSHOT (2026)
FIGURE 35 ALPHABET INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 RECURSION: COMPANY SNAPSHOT (2025)
FIGURE 37 INSILICO MEDICINE: COMPANY SNAPSHOT (2025)
FIGURE 38 SCHR?DINGER, INC.: COMPANY SNAPSHOT (2025)
FIGURE 39 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2026)
FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 41 XTALPI INC.: COMPANY SNAPSHOT (2025)
FIGURE 42 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
FIGURE 43 CERTARA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 44 RESEARCH DESIGN
FIGURE 45 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 46 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 47 BOTTOM-UP APPROACH
FIGURE 48 TOP-DOWN APPROACH
FIGURE 49 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AI IN DRUG DISCOVERY INDUSTRY
FIGURE 50 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 51 DATA TRIANGULATION METHODOLOGY
More Publications
Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024
US$ 3,390.00
April 2019
113 pages
Vitamin D Market by Analog (Vitamin D2, Vitamin D3), Form (Dry, Liquid), Application (Feed & Pet Food, Pharma, Functional Food, and Personal Care), End Users (Adults, Pregnant Women, and Children), IU Strength and Region - Global Forecast to 2027
US$ 2,970.00
November 2022
269 pages
US General Anesthesia Drugs Market by Route of Administration (Intravenous and Inhalational), End User (Hospitals, Ambulatory Surgery Centers) - Forecast to 2025
US$ 2,970.00
February 2021
117 pages
